World CDx: Discovery, Development & Commercialization of Companion Diagnostics

Tuesday, November 13 – Thursday, November 15 2012

Location: Boston

The Most Important Meeting of CDx Minds in the World

 In 2012, World CDx will take a more detailed look at the unanswered questions facing drug developers working with Companion Diagnostics, Dx and technology providers as well as clinicians, payers, regulators and patients. 

 Bringing you 50+ speakers, 200+ attendees, 2 highly focused conference streams, interactive workshops, and an unbeatable networking calendar, World CDx is the forum for drug developers and Dx pioneers to learn, network and do business.

 After the ‘CDx Summer’ of 2011, 2012 is looking promising for Companion Diagnostics. As big-time drug developers and diagnostics firms continue to join forces, the gap between CDx development & commercialization is steadily decreasing. As the pharma industry increasingly ramps up its diagnostic efforts, expect nichebusters to play an increasingly important role in healthcare

But questions still remain: How best to get around the pitfalls of taking companion diagnostics from the lab to the bedsides of patients. How to ensure mutually beneficial reimbursement models, increase regulatory cooperation, and build the best commercial partnerships. How to achieve seamless biomarker validation and make the most of genomic data…the list goes on. Isn’t it time they were all addressed? 

World CDx is the only meeting to examine the impact of companion diagnostic development on commercial partnerships, drug marketability and patient care, where you can learn from the experiences and perspectives of ALL stakeholders in the personalized medicine space, in order to develop more effective companion diagnostics

***Mass Bio members are eligible for a 10% discount off the registration fee.***

Simply quote ‘MASSBIO’ when registering.

To register:

Online: http://world-cdx.com/register

By email:register@hansonwade.com 

By phone: +1 212 537 5898                               

Share MassBio

 

BioProcess

EvaluatePharma 

MassBio